Short Bowel Syndrome Drugs Market : Industry Perspective, Comprehensive Analysis, Growth, Segment, Trends and Forecast

The buyer may better understand the different drivers and restraints and how they will affect the market over the projected term with the use of a Short Bowel Syndrome Drugs Market research study. It also sheds light on recent advancements, new product releases, partnerships, mergers, and acquisitions that a number of important companies and brands have embraced. The best Short Bowel Syndrome Drugs Market study provides CAGR estimates for the base year 2022, the historic year 2021, and the forecast period of 2023–2030 in addition to evaluations of all the market drivers and constraints, which are primarily derived from SWOT analysis.

The superior Short Bowel Syndrome Drugs Market research study has been organized using the knowledge and creativity of a group of analysts, managers, forecasters, and researchers. The company profile, product details, capacity, production value, and market shares for each company from 2023 to 2030 are shown in this market report. This market study includes company profiles of major industry participants, a detailed examination of their core strengths, and a competitive landscape drawing. This expertly written study goes into great detail and focuses on major segments, market share, primary and secondary drivers, and geographic analysis. In order to create a great Short Bowel Syndrome Drugs Market business report, excellence and intelligibility are two of the most important criteria that must be met.

Explore Further Details about This Research Short Bowel Syndrome Drugs Market Report https://www.databridgemarketresearch.com/reports/global-short-bowel-syndrome-drugs-market

Short bowel syndrome is related with small intestine surgeries. It is characteristically acquired over the individual’s lifespan and genetically occurs only in few cases. Currently, there is no cure for short bowel syndrome and the treatment is targeted toward its symptoms. In some cases, short bowel syndrome can be life-threatening, but the disease can be managed through effective medication. In addition to this, government bodies are directly taking part in boosting the confidence of local manufacturers through various initiatives.

Data Bridge Market Research analyses a growth rate in the global short bowel syndrome drugs market in the forecast period 2022-2029. The expected CAGR of global short bowel syndrome drugs market is tend to be around 15% in the mentioned forecast period. The market was valued at USD 1.44 billion in 2021, and it would grow upto USD 4.40 billion by 2029. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Short bowel syndrome drugs is a type of rare gastrointestinal disease wherein a patient either lose a large amount of intestine or are born with inadequate amount of intestine as well as dysfunctional intestine that finally results in the malnutrition because it cannot effectively absorb the nutrients from the food.

Drivers

Increased Demand of Intravenous Supplementation of Fluids

There is a rising demand for intravenous supplementation of fluids for maintaining the normal hydration and urinary flow for patients who are suffering from this syndrome. Several key manufacturers in the short bowel syndrome market are making efforts to meet this demand, since these patients suffer from complications such as hyponatremia, dehydration, and chronic renal failure. Hypomagnesemia is caused by malabsorption of magnesium because of the loss of the distal ileum, several manufacturers are producing magnesium supplements to help the patients achieve adequate hydration.

Prevalence of Short Bowel Syndrome

Incidence of short bowel syndrome has increased across the globe in the past few years. The increasing patients number on total parenteral nutrition has led to the increase in the market growth. The occurrence of short bowel syndrome is projected to be about four people per million, and the occurrence is about three people per million. Although the exact prevalence of the disease is not clear, it is expected based on the number of people on parenteral nutrition.

Recent Development

In June 2021, VectivBio Holding AG announced that the FDA had granted orphan drug designation to Apraglutide. It is a next-generation, long-acting GLP-2 analog that is being developed for rare gastrointestinal diseases and used for the prevention of acute graft-versus-host disease (aGVHD).
In April 2021, Hanmi Pharm. Co. Ltd. announced that the U.S. FDA had granted fast-track designation to its short-bowel syndrome therapy, LAPS GLP-2 Analog (HM15912). LAPS GLP-2 Analog is a new biopharmaceutical that has been developed for short-bowel syndrome with the company's platform technology, Labscovery. The disorder occurs in approximately 24.5 out of 100,000 newborns and majorly affects the growth of children and adolescents, with a survival rate under 50%.

Global Short Bowel Syndrome Drugs Market Scope

The global short bowel syndrome drugs market is segmented on the basis of drug class, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

Glucagon-like Peptide
Anti-Diarrheal
Histamine Blockers
Proton Pump Inhibitors
Growth Hormone
Others

Route of Administration

Oral
Parenteral
Others

End User

Hospitals
Homecare
Specialty Clinics
Others

Distribution Channel

HospitalPharmacy
Online Pharmacy
Retail Pharmacy

Key players operating in the global short bowel syndrome drugs market include:

Takeda Pharmaceutical Company Limited (Japan)
Johnsons Johnsons Services Inc (U.S.)
Boehringer Ingelheim International GmbH (Germany)
Sun Pharmaceutical Industries Ltd. (India)
Sanofi (France)
GSK Plc. (U.K.)
Novartis AG (Switzerland)
Pfizer Inc. (U.S.)
Amneal Pharmaceuticals LLC. (U.S.)
Alvogen (U.S)
Hikma Pharmaceuticals PLC (U.K.)

Key Insights Of Short Bowel Syndrome Drugs Market Report

The report comprises a detailed analysis of different segments and offers market valuations between 2023 to 2030.
This study presents the analytical depiction of the Short Bowel Syndrome Drugs Market with the current trends and future estimations to determine the imminent investment pockets
The report also reveals information with respect to key drivers, restraints, and opportunities coupled with a comprehensive analysis of the global Short Bowel Syndrome Drugs Market
The forecast period of the market is assessed from 2024 to 2030 to highlight the Short Bowel Syndrome Drugs Marketgrowth scenario.
Porter’s five forces analysis establishes the effectiveness of the buyers and suppliers in the business line.
The key players in the industry are profiled to gain an understanding of the strategies adopted by them.
This report provides the current trends and future estimations during the forecast period, which in turn aids in identify the prevailing market opportunities.

The company portfolio includes company synopsis, operating business sectors, business overview, product/service categories, and recent growth strategies adopted by them.

Browse Related Reports: